Advicenne: 2021 Financial Calendar
23 Avril 2021 - 5:45PM
Business Wire
Regulatory News:
Advicenne (Euronext: ADVIC) today publishes its indicative
financial calendar for the financial year 2021.
Event
Date*
Annual results 2020
Wednesday, April 28, 2021
General Meeting
Monday, June 14, 2021
Half-Year Results 2021
Thursday, September 30, 2021
Financial year end on December 31
* Subject to change. Publication after
market close.
About Advicenne
Advicenne (Euronext: ADVIC) is a pharmaceutical company founded
in 2007, specializing in the development of innovative treatments
in Nephrology. Its lead drug candidate is currently in late-stage
clinical trials for two kidney diseases: the renal tubular acidosis
and cystinuria. ADV7103 has recently received a positive CHMP
opinion for the treatment of dRTA.
Headquartered in Paris, Advicenne has been listed on the
Euronext Paris stock exchange since 2017 and was cross-listed on
the Euronext Brussels stock exchange in 2019.
For additional information see: www.advicenne.com
Forward-Looking Statements
This press release contains certain forward-looking statements
relating to the business of Advicenne, which shall not be
considered per se as historical facts. Such statements include
projections and estimates, and the hypotheses on which these are
based, as well as observations relating to operations, ongoing
projects, objectives, the development of products and their future
performance, and expectations regarding financial results.
In some cases, forward-looking statements can be identified by
words such as "could," "should," "may," "expects," "anticipates,"
"believes," "intends," "estimates," "aims," "targets" or similar
words. Although the management of Advicenne believes that these
forward-looking statements are reasonably made, investors should be
aware that they are subject to a number of known and unknown risks
and uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
these forward-looking statements. In particular, the expectations
of Advicenne could be affected by, among other things,
uncertainties involved in the placing on the market and
commercialization of Advicenne products or any other risks and
uncertainties developed or identified in any public documents filed
by Advicenne with the French Financial Markets Authority (Autorité
des marchés financiers (AMF)), including those listed in Chapter 4,
“Risk Factors,” of its universal registration document, filed with
the latter on December 22, 2020. Notwithstanding the compliance
with article 223-1 of the General Regulation of the AMF (the
information disclosed must be “accurate, precise and fairly
presented”), Advicenne disclaims any intention or obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210423005078/en/
Advicenne David Solomon, Chairman +33 (0)4 66 05 54 20
investors@advicenne.com
Financial communications NewCap Dusan Oresansky, Emmanuel
Huynh +33 (0)1 44 71 94 94
Press Relations NewCap Nicolas Merigeau +33 (0)1 44 71 94
98 advicenne@newcap.eu